Introduction
Previous epidemiological studies have established a link between diabetes and increased prevalence of peripheral artery disease (PAD) (1, 2) . It was also found that patients with diabetes and PAD are at greater risk for lower extremity amputation, cardiovascular and cerebrovascular events compared with patients without diabetes (1, 2) . The Edinburgh Artery Study showed that after 5 years of follow-up both symptomatic and asymptomatic patients with PAD had increased risk for cardiovascular death (3) . In addition, the German Epidemiological Trial on Ankle Brachial Index (ABI) pointed out a higher rate of cardiovascular events and death both in asymptomatic and symptomatic patients with ABI below 0.90 (4) . On the other hand, the Framingham Heart Study revealed that approximately 20% of patients with symptomatic PAD have diabetes. It was also shown that the prevalence of PAD in patients with diabetes is greatly underestimated, given that more than 80% either have atypical symptoms or no symptoms at all (5) .
Besides diabetes, the strongest risk factors for PAD are older age (6) and cigarette smoking (7) . Other potential risk factors include hypertension (8) and dyslipidemia: elevations of total cholesterol (Ch), low-density lipoprotein cholesterol (LDL-Ch), triglyceride (TG) and lipoprotein (Lp) (a) levels (6) . A followup study published in 2012 showed that insulin resistance analyzed by the homeostatic model of insulin resistance (HOMA-IR) was associated with a higher risk of PAD measured by ABI (9) . Findings from the National Examination Survey, 1999 to 2004 demonstrated a strong and independent relationship between insulin resistance as assessed by HOMA-IR and PAD defined as ABI≤0.9 (10) . Lately, high-sensitivity C-reactive protein (hs-CRP) has been indicated as a potential marker for the presence of PAD, but also as a factor that probably participates in the development and progression of the illness. CRP is produced primarily in the liver as a result of a non-specific acute response to tissue damage, infection, inflammation and malignant neoplasia (11) . It binds with high affinity to phospholipids in apoptotic cells and damaged cell membranes, oxidized lipoproteins and cells attacked by microorganisms. Also, it was found that CRP can bind to lipoproteins and damaged cells in the atherosclerotic plaque to induce complement activation, thereby promoting inflammation and disease progression (11) . The data, primarily from in vitro studies, suggest the possibility that CRP itself contributes to the development and progression of atherosclerosis, and that it can be considered not only as a marker but also as a genuine risk factor. CRP levels, thus, could reflect the severity of atherosclerosis and risk of future cardiovascular events. However, the detailed mechanisms of the role of CRP in the development of PAD in patients with type 2 diabetes have not yet been elucidated. For that reason, this follow-up study aimed to evaluate the possible predictive significance of hs-CRP for PAD development and progression in patients with type 2 diabetes.
Methods
In this prospective, cohort observational study, we assessed the relationship between hs-CRP and the occurrence and progression of PAD in patients with type 2 diabetes. The study was carried out according to Good Clinical Practice and was approved by the local medical Ethics Committee and conformed to the principles outlined in the Declaration of Helsinki (12) . All patients included in the study gave their written Informed Consent.
Study population
From a larger group of patients, 80 patients previously diagnosed with type 2 diabetes, aged 45-70 years, were randomly chosen for the study from our outpatient clinic. After a thorough basal examination, patients were divided according to the presence of PAD (based on the value of ABI) into two groups: group A consisted of patients with PAD (n=38) and group B consisted of patients without PAD (n=42). After five years, all the patients were re-examined and divided into subgroups depending on de novo development of PAD or progression of previously diagnosed PAD. All patients included in the study were treated with diet and/or oral antidiabetic drugs only. The patients treated with insulin as well as smokers (former or current) were excluded. Subjects with ABI less than 0.40 and/or ABI greater than 1.30, subjects with CRP>10 g/L, and subjects who refused to be followed and investigated were excluded also. We excluded patients with acute or chronic infectious disease, renal disease, hepatic disease, malignancies, autoimmune disorders and chronic inflammatory diseases. Medications that might affect lipoprotein levels were discontinued 24-48 h before testing. Participants did not receive medications and/or foods that might affect glucose levels at least 12 hours before providing blood samples for analysis.
Degree of obesity was determined by using the body mass index (BMI) which was calculated according to the formula: BMI (kg/m 2 ) = body weight (kg) / body height (m 2 ) (13). The type of obesity was determined by the value of waist circumference and waist to hip ratio (WHR) (14, 15) . Coronary and cerebrovascular diseases were diagnosed on the basis of medical history and data from relevant medical records. Hypertension was defined as systolic/diastolic blood pressure (≥140/≥90 mmHg) according to the previous description as recommended by the World Health Organization (WHO) and ESH/ESC Guide li nes for management of arterial hypertension (16), or by a patient's history of antihypertensive therapy.
Vascular assessment
Diagnosis of PAD was based on the ABI on either leg, as previously described (17) . Briefly, Doppler ultrasound (The Huntleigh Multi Doppler II Bi-directional Doppler with an 8 MHz vascular probe) was used to measure systolic pressure in the bilateral brachial, posterior tibial and dorsal pedal arteries. ABI was calculated by dividing the higher pressure in the dorsal pedal and posterior tibial arteries on the right and left sides respectively by the higher brachial pressure on either side (at least two measurements were done).
PAD diagnosis and categorization based on the determination of ABI were interpreted as follows: without PAD: ABI of 0.91-1.30; mild obstruction: ABI of 0.70-0.90; moderate obstruction: ABI of 0.41-0.69; severe obstruction: ABI less than 0.40; and non-compressible blood vessels when ABI is greater than 1.30 (due to medial arterial calcification) (17).
After 5 years of follow-up, ABI measurements were repeated in all patients and we determined an ABI decline from one category to another (from mild to moderate and from moderate to severe) as a marker of PAD progression, and an ABI decline from normal to values below 0.90 as a marker of de novo PAD development in these patients.
Laboratory analyses
From each patient included in the study blood samples for laboratory analyses were drawn after a 12-14 hours overnight fast, twice: at the beginning of the study and after 5 years.
Venepunction (two tubes BD Vacutainer -one SST® II Advance and one with K 2 EDTA) was performed after overnight fasting. Serum was separated by centrifugation for 15 minutes at 1500 g, and used for the measurement of glucose, total, HDL-and LDL-cholesterol, triglyceride and CRP concentrations, while the HbA1C concentration was measured in the whole blood samples collected with K 2 EDTA. All biochemical parameters were measured immediately after collection. Commercial tests produced by Beckman Coulter ® (USA) were used to measure the concentration of glucose (hexokinase/glucose-6-phosphate dehydrogenase (G-6-PDH) method), HbA1c (immuno-inhibition method), cholesterol (method based on the coupled action of cholesterol oxidase (CHO) and peroxidase (POD)), HDL-and LDL-cholesterol (direct homogenous assays) and triglycerides (method utilizing a series of reactions catalyzed by lipase, glycerol kinase (GK), glycerol phosphate oxidase (GPO) and peroxidase (POD)). All the mentioned tests were performed on the analyzer Beckman Coulter AU 400 ® . For hs-CRP concentrations, commercial immunoassay reagent kits manufactured by Siemens Healthcare ® were used and tests were performed on the Behring Nephelometer Analyzer II ® .
The levels of analyzed high-sensitivity CRP (hs-CRP) were classified as low (<1 mg/L), intermediate (1 to 3 mg/L) and elevated (>3 mg/L) according to the American Heart Association and Centers for Disease Control (18) .
Plasma insulin levels were determined by the radioimmunoassay method (PEG, INEP Insulin RIA kit) according to the standardized WHO reference preparation. Insulin resistance (IR) was assessed by HOMA-IR, which was calculated by the formula: HOMA-IR = insulin (mIU/L) × fasting glucose (mmol/L) / 22.5 (19) (20) (21) (22) .
Statistical analyses SPSS 10.0 for Windows v18 (SPSS Inc, Chicago Ill) was used for statistical analysis. Values and the results are expressed as mean ± standard deviation (SD) and descriptive statistics were calculated to summarize the clinical features of the patients. Normality of variable distribution was assessed using the Kolmogorov-Smirnov test. For testing the difference between groups we used the Student t-test for variables with normal distribution, and for data without normal distribution we used the Mann-Whitney U test. Receiver operating characteristic curves (ROC) were used to determine a cut-off value for hs-CRP that would discriminate patients at risk for PAD development/progression. A forward stepwise multivariate binary logistic regression analysis was conducted to identify independent predictors of PAD progression, and odds ratio (OR) with the 95% confidence interval (CI) was determined. All the tests used were twotailed and p-values less than 0.05 were considered significant.
Results
The clinical and anthropometric characteristics of type 2 diabetes patients involved in the study are shown in Table I . No significant differences were seen among the groups with respect to mean age, duration of diabetes, BMI and presence of diabetic complications (retinopathy, nephropathy and polyneuropathy and coronary artery disease). However, claudication was more prevalent in group A in comparison to group B, as well as in subgroups A1 and A2 in comparison to subgroups B1 and B2 (p<0.05). Also, waist circumference was significantly higher in group A compared to group B at the beginning of study (first exam, p<0.05), but we failed to find such a difference at the 5-year follow-up (second exam) (data not shown).
As for fasting glucose, HbA1c, lipid parameters, plasma insulin and HOMA IR, their levels were similar in both groups (A and B) at the first, as well as at the second exam after 5 years. Additionally, when we compared these parameters in patients from subgroups A1 (progressors) and A2 (non-progressors), as well as from subgroups B1 (progressors) and B2 (non-progressors), at the first and second exam, we also failed to find any significant differences (data are shown in Table II ).
Simultaneously, we found significantly higher hs-CRP levels in group A (with PAD) compared to group B (without PAD), but only at the first exam (Table II) . Among the patients in group A, those with later progression of PAD (subgroup A1) had the high- est level of hs-CRP at the first exam, although this value was not significantly different from that in patients from subgroup A2 (non-progressors), neither at the first nor at the second exam (data are shown in Table III ). By contrast, the hs-CRP level was significantly higher in subgroup B1 (progressors) in comparison to subgroup B2 (non-progressors) at both the first and the second exam after 5 years (data are shown in Table IV ). Also, the majority of patients in subgroups A1, A2, and B1 had elevated hs-CRP levels (>3 mg/L) according to AHA and CDC (20) , but the majority of patients in subgroup B2 had intermediate levels (1-3 mg/L) ( Table II) .
In order to establish whether the determination of hs-CRP might be useful for prediction of the existence, development and progression of PAD, patients with PAD at the beginning of the study and those in whom PAD developed or progressed during 5 years (subgroups A1, A2 and B1, n=60) were compared to patients who remained PAD-free during the whole follow-up period (subgroup B2, n=20). The level of hs-CRP was significantly higher in all patients with PAD at the beginning of the study (first exam, p<0.01) and also five years later (second exam, p<0.001) when compared to those who remained PAD-free (Figure 1 ).
Forward stepwise multivariate logistic regression analysis showed that the only potentially significant predictor of PAD was hs-CRP (HR=1.961, 95% CI=1.295-2.976, p=0.001). In addition, of all the investigated metabolic parameters, hs-CRP was the only independent predictor of PAD development and HOMA-IR-HOMA insulin resistance index; hs-CRP-high-sensitivity C-reactive protein; Ch-cholesterol, results are shown as mean ± standard deviation (X±SD); for testing the difference between groups and subgroups we used Mann-Whitney U test for data without normal distribution *, and student t test** if data had normal distribution. * ** Figure 1 Mean values of hs-CRP at baseline (first exam) and after 5 years of follow-up (second exam) in patients with PAD (subgroups A1, A2 and B1, n=60) and in patients without PAD (subgroup B2, n=20), *p=0.000, ** p=0.000. AUC -area under the receiver-operating curve; dCI -confidence interval; hs-CRP -high sensitivity C-reactive protein; HOMA-IR -HOMA insulin resistance index. progression in the ROC analysis (AUC=0.780, SE=0.052, 95% CI=0.678-0.882, p=0.000) ( Table  III, Figure 2) . Moreover, the cut-off point for hs-CRP was 2.5 mg/L, with 75% specificity and 73.3% sensitivity (c 2 =14.76, p<0.001). The cut-off for hs-CRP tested by the Cochran Mantel-Haenszel method (24, 25) was also used for differentiating patients with PAD (subgroups A1, A2, B1) and those without PAD (subgroup B2). Odds Ratio for the obtained cut-off point for hs-CRP was 8.25 (95% CI=2.58-26.39, p<0.000) which indicates that the relative risk for PAD was almost three times higher if the value of hs-CRP was greater than or equal to 2.5 mg/L (RR=2.933, 95% CI 1.35-6.36).
Discussion
Data presented in this 5-year follow-up study showed that among the traditional and non-traditional risk factors investigated (age, BMI, waist circumference, HbA1c, lipids, IR) hs-CRP represents the most important predictive biomarker not only for the presence of PAD, but also for new development and/or progression of existing PAD in patients with type 2 diabetes. Furthermore, our results indicated that the hs-CRP level of 2.5 mg/L might be the discriminative value above which the risk for development and/or progression of PAD in patients with type 2 diabetes increases significantly (approximately three times). Our results are in agreement with the results of several published studies that have pointed out CRP as an independent risk factor for PAD and suggested that patients with increased levels of CRP also have twofold increased risk for PAD development (25) .
It has been previously shown that PAD, as a manifestation of atherosclerotic vascular disease, is more prevalent and tends to be much more severe in patients with type 2 diabetes, but presence of PAD in these patients also significantly increases the risk for ulcers, gangrene and amputation (26) . Given that the traditional risk factors such as hyperglycemia, hyperlipidemia and smoking do not fully explain why PAD is more common and has serious clinical consequences in patients with diabetes, a number of studies have investigated the association of novel risk factors and biomarkers with PAD. In recent years, an increasing body of evidence has supported the finding that inflammation could play an important role in the development and progression of atherosclerosis (27) , but the association of inflammation and various acute phase proteins, particularly CRP, with PAD has not yet been clarified. Recent findings suggest that CRP, as an inflammatory marker, could be used to assess cardiovascular risk (28) . As demonstrated in a comprehensive meta-analysis of 54 prospective cohort studies, hs-CRP was an independent risk factor for future cardiovascular events characterized by a magnitude of effect similar to or larger than that of blood pressure or cholesterol and long-term stability and reproducibility, at least as good as these widely-accepted risk factors (29) .
Ridker et al. (30) were the first to indicate a link between CRP and PAD, independent of other risk factors (31, 32) . The National Academy of Clinical Biochemistry clearly pointed out that hs-CRP is the only emerging risk marker for clinical use, considering its characteristics and the results of some prominent studies such as JUPITER, PROVE-IT and A to Z (33) .
In some of the previously published prospective studies, a major novel finding was that the basal levels of CRP were significantly higher in patients who later, during the follow-up, developed PAD and that CRP was also the strongest predictor for PAD (34) . The Edinburgh Artery Study identifies CRP as a predictor of the development and progression of PAD (35) and Van der Meer and his colleagues confirm the importance of hs-CRP in the assessment of PAD progression (36).
Our results have confirmed these findings regarding the presence of increased hs-CRP not only in type 2 diabetes patients with established PAD, but also in the patients who went on to develop PAD. In our study we used ABI as a marker of PAD, and also as a measure of PAD progression in patients with type 2 diabetes. So, the diagnosis of PAD was not based on imaging methods (like arteriography and other visualization techniques) which could influence the results, especially given that almost one third of patients without PAD according to the ABI method (group B) had claudication. However, nowadays, the ABI is widely used in clinical practice to establish the presence of PAD. Also, as a noninvasive measure of systemic atherosclerotic disease, the ABI is a valuable tool for investigating the relationship between novel biomarkers and atherosclerosis, particularly PAD, in a large number of subjects, which was the reason for using this method in our study. A number of investigations used ABI and found a significant inverse relationship between ABI and CRP levels (37, 38) , or even a link between CRP, PAD severity (assessed by using the ABI) and future cardiovascular events (26) . The added value of our investigation might be the set up of a cut-off point for hs-CRP (2.5 mg/L) as a predictive value for future PAD, with satisfactory sensitivity (73.3%) and specificity (75%). This may be useful in clinical practice, at least in our clinical settings, to identify patients with type 2 diabetes at higher risk for development or progression of PAD.
A possible shortcoming of our study primarily relates to the relatively small number of patients analyzed and the relatively short length of follow-up (5 years). However, patients engaged in our research were carefully chosen from the large number of type 2 diabetes patients treated in our outpatient service who met the strict inclusion criteria. We excluded those with acute inflammatory illness, other acute and chronic diseases and malignancy, smokers, etc, to avoid possible confounding factors. Moreover, when comparing patients with and without PAD, we failed to find any difference in the level of metabolic control of diabetes, degree of obesity, IR and lipid parameters at the beginning of the study and after 5 years which further emphasizes the importance of hs-CRP as an independent predictive biomarker for future PAD. It has to be noted that future studies should include examinees followed from the time of diagnosis of diabetes in order to determine whether the increased levels of CRP precede the occurrence of PAD or are simply a side effect of the already established PAD. In this regard, we have planned to continue the follow-up of these groups of patients with re-evaluation after a ten-year interval.
In conclusion, our prospective study indicates that patients with type 2 diabetes and elevated levels of hs-CRP have almost 3-fold higher risk for PAD irrespective of the present moderate degree of obesity, hyperglycemia and dyslipidemia. The data presented also suggest that hs-CRP can be used as a reliable predictor for PAD progression in patients with type 2 diabetes.
